An Open-labelled, Randomized Phase II Study to Investigate Efficacy of Autologous Lymphoid Effector Cells Specific Against Tumour-Cells (ALECSAT) in Patients With GBM Measured as Progression Free Survival Compared to Avastin/Irinotecan

Trial Profile

An Open-labelled, Randomized Phase II Study to Investigate Efficacy of Autologous Lymphoid Effector Cells Specific Against Tumour-Cells (ALECSAT) in Patients With GBM Measured as Progression Free Survival Compared to Avastin/Irinotecan

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Cancer vaccine-ALECSAT (Primary) ; Bevacizumab; Irinotecan
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors CytoVac
  • Most Recent Events

    • 16 Jun 2015 Planned End Date changed from 1 Mar 2017 to 1 Sep 2015 as per ClinicalTrials.gov.
    • 16 Jun 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
    • 24 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top